
|Videos|March 23, 2022
Data suggest radium-223 and PSMA-targeted radionuclides are well tolerated in prostate cancer
Author(s)Urology Times staff
“We look forward to the optimization of these drugs,” says Scott T. Tagawa, MD, MS, FACP.
Advertisement
In this video, Scott T. Tagawa, MD, MS, FACP, discusses the main points of the presentation, “Therapeutic radiopharmaceuticals: Past, present, and future,” which was given recently at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA updates in urology: May 2026
4
FDA approves cefepime and zidebactam for complicated UTI
5











